Journal of Movement Disorders

Jae Wook Cho

2 Articles

Spinocerebellar Ataxia 13 Presenting with Pure Cerebellar Syndrome in a Korean Family: Minkyeong Kim, Seung Hwan Oh, Jae Wook Cho, Jae-Hyeok Lee; J Mov Disord. 2020;13(3):244-246. Published online September 9, 2020; DOI: https://doi.org/10.14802/jmd.20064

4,443 View
77 Download
1 Web of Science
1 Crossref

PDF

Citations

Citations to this article as recorded by

A Review of Ocular Movement Abnormalities in Hereditary Cerebellar Ataxias
Mehri Salari, Masoud Etemadifar, Ronak Rashedi, Sayna Mardani
The Cerebellum.2023; 23(2): 702. CrossRef

Suppression of Myoclonus in Corticobasal Degeneration by Levetiracetam: Jae Wook Cho, Jae Hyeok Lee; J Mov Disord. 2014;7(1):28-30. Published online April 30, 2014; DOI: https://doi.org/10.14802/jmd.14007

10,598 View
103 Download
12 Web of Science
11 Crossref

Abstract PDF

Myoclonus in corticobasal degeneration (CBD) has often been associated with severe and difficult to treat disabilities. Levetiracetam is a new antiepileptic agent with antimyoclonic effects. Herein, we present a 72-year-old woman with clinically probable CBD and with spontaneous rhythmic myoclonus in the right foot, which was markedly ameliorated through treatment with levetiracetam. The effect of levetiracetam was associated with the decreased amplitude of enlarged cortical somatosensory evoked potentials. This result suggests that the antimyoclonic effect of levetiracetam might be mediated through the suppression of increased cortical excitability.

Citations

Citations to this article as recorded by

Management Strategies for Atypical Parkinsonism
Vasilios C. Constantinides, Nikolaos Giagkou, Maria-Evgenia Brinia, Christos Koros, Leonidas Stefanis, Maria Stamelou
Current Treatment Options in Neurology.2024; 26(5): 169. CrossRef
Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
Abdullahi Alausa, Sunday Ogundepo, Barakat Olaleke, Rofiat Adeyemi, Mercy Olatinwo, Aminat Ismail
Chinese Medicine.2021;[Epub] CrossRef
Four-Repeat Tauopathies: Current Management and Future Treatments
Lawren VandeVrede, Peter A. Ljubenkov, Julio C. Rojas, Ariane E. Welch, Adam L. Boxer
Neurotherapeutics.2020; 17(4): 1563. CrossRef
Physiology-Based Treatment of Myoclonus
Ashley B. Pena, John N. Caviness
Neurotherapeutics.2020; 17(4): 1665. CrossRef
Pharmacological interventions in corticobasal degeneration: a review
Leonardo Caixeta, Victor de Melo Caixeta, Yanley Lucio Nogueira, Tales Alexandre Aversi-Ferreira
Dementia & Neuropsychologia.2020; 14(3): 243. CrossRef
Available and future treatments for atypical parkinsonism. A systematic review
Davide Vito Moretti
CNS Neuroscience & Therapeutics.2019; 25(2): 159. CrossRef
An Update on Myoclonus Management
Christine M. Stahl, Steven J. Frucht
Expert Review of Neurotherapeutics.2019; 19(4): 325. CrossRef
Corticobasal degeneration: key emerging issues
F. Ali, K. A. Josephs
Journal of Neurology.2018; 265(2): 439. CrossRef
Focal Predominant Forms of Posthypoxic Action Myoclonus
Carmen Gasca‐Salas, Anthony E. Lang
Movement Disorders Clinical Practice.2016; 3(4): 417. CrossRef
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Ruth Lamb, Jonathan D. Rohrer, Andrew J. Lees, Huw R. Morris
Current Treatment Options in Neurology.2016;[Epub] CrossRef
An Update and Review of the Treatment of Myoclonus
Kelly Mills, Zoltan Mari
Current Neurology and Neuroscience Reports.2015;[Epub] CrossRef

Author index